You are here : Home / All Sectors / Healthcare / Pharmaceuticals & Drugs / CIPLA

CIPLA
Intrinsic Value | Fundamental Analysis

Returns | 1W : 1.5% , 1M : 5.5%,1Y : 19.6%
www.cipla.com
BOM : 500087     NSE : CIPLA    
LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Average [Stock is fairly valued]
Debt : Low
Updated:
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Upward
Pledged Shares : None or < 25%
Sep 24,2021
Price(EOD): Rs. 967.00
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
Affiliate Link.
Stock Market Investing Simplified- The best Video Course by Smart-Investing.in

Check out Industry Peers

Peers & Returns1W1M1Y
CIPLA 1.5% 5.5% 19.6%
SUN PHARMACEUTICAL INDUSTRIES -0.1% -0.3% 47.1%
DIVIS LABORATORIES 1.7% 7.3% 53.8%
DR REDDYS LABORATORIES -1.9% 4.5% -9%
GLAND PHARMA -1.6% 2.6% NA
PIRAMAL ENTERPRISES 5.6% 6.6% 95.6%
CADILA HEALTHCARE 1.6% 3.3% 37.2%
TORRENT PHARMACEUTICALS 0.2% 1.5% 7.4%
ALKEM LABORATORIES 5.7% 4.8% 38.4%


FUNDAMENTAL ANALYSIS OF CIPLA

 
Fundamentals Score
[ Q(TTM): Jun2021, Y: Mar2021
Q : Last Qtr data
Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
]
Show Me the Stocks with Fundamentals better than CIPLA Plus/Pro


VALUATION OF CIPLA

 
Valuation Score
[As on : Sep 24,2021 ]

Ratio Consolidated
P/E
P/B
P/S
32.43
P/E Calculated based on EPS of 29.82
[ Mar2021 - Consolidated Results ]

4.26
P/B Calculated based on Book Value of 226.73
[ Mar2021 - Consolidated Results ]

3.84
P/S Calculated based on Revenues of 20317.8 Cr
[ TTM - Consolidated Results ]

Show Me the Stocks with Valuation better than CIPLA Plus/Pro


FAIR VALUE OF CIPLA

 
Model Discount(-)/
Premium(+)
EV/EBIDTA
EV/Sales
Price/Sales
10%
6%
7%

SHARE PRICE MOMENTUM OF CIPLA

DEBT

Year Debt/Equity ratio
Standalone Consolidated
2021
2020
2019
Avg_3yrs
0
0
0
-
0.1
0.18
0.29
0.19
[Last Annual Data : Mar2021]

PLEDGED SHARES

Pledged Shares
0 %
As on : Jun2021

If less than 25%

Good
If between 25% and 50% Neutral
If greater than 50% Bad

QTRLY RESULTS

Consolidated Q-o-Q Y-o-Y
Revenue
Op Profit
Profit Before Tax
Profit After Tax
19.49%
69.03%
83.09%
71.31%
26.65%
28.33%
24.56%
24.56%
QtrlyTrend
8
Latest Qtr: Jun2021

CIPLA related INDICES

BSE Indices1W1M1Y
S&P BSE DIVIDEND STABILITY 3% 7.3% 49.6%
S&P BSE MOMENTUM 2.8% 7.2% 41.8%
S&P BSE SENSEX50 2.6% 7.2% 54.8%
S&P BSE LARGECAP 2.5% 7.3% 54.6%
S&P BSE LARGE MIDCAP 2.5% 7.6% 56.6%
S&P BSE 100 2.5% 7.4% 55.5%
S&P BSE CARBONEX 2.5% 7.2% 54.9%
S&P BSE 250 LARGEMIDCAP 2.5% 7.6% 57.8%
S&P BSE 200 2.5% 7.6% 57.5%
S&P BSE 100 LARGECAP TMC 2.5% 7.4% 55.3%
S&P BSE 500 2.5% 7.7% 59.1%
S&P BSE ALLCAP 2.4% 7.7% 60.1%
S&P BSE GREENEX 2.4% 6.9% 56%
S&P BSE 100 ESG INDEX 2.1% 6.5% 54.7%
MFG 1.6% 5.8% 41.7%
S&P BSE HEALTHCARE 0.4% 1.9% 30.3%
NSE Indices1W1M1Y
NIFTY 50 2.6% 7.3% 54.9%
NIFTY 200 2.5% 7.8% 57.6%
NIFTY LARGE MIDCAP 250 2.5% 8.3% 63.2%
NIFTY 100 2.5% 7.5% 55.4%
NIFTY 500 2.5% 7.8% 59.1%
NIFTY50 EQUAL WEIGHT 2.4% 7.5% 65.3%
NIFTY500 MULTICAP 50:25:25 2.4% 8.1% NA
NIFTY 100 EQUAL WEIGHT 2.2% 7.9% 63.1%
NIFTY ALPHA LOW-VOLATILTY 30 2.1% 8.2% 47.8%
NIFTY 100 ALPHA 30 1.8% 6.6% NA
NIFTY100 LOW VOLATILITY 30 1.6% 7.1% 46.8%
NIFTY PHARMA 1.4% 3.3% 16.7%
NIFTY HEALTHCARE 0.6% 1.5% NA

FAQ [Frequently Asked Questions]


Is CIPLA good for long term investment?

As on 24-Sep-2021, the Fundamentals of CIPLA look Strong and hence it may be good for long term investment! See Financial Performance of CIPLA . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!

Is CIPLA UnderValued or OverValued?

As on 24-Sep-2021, CIPLA is Fairly Valued based on the estimates of intrinsic value and investors may wait for the buying opportunity once it becomes under valued!

What is the Intrinsic Value of CIPLA ?

As on 24-Sep-2021, the Intrinsic Value of CIPLA is Rs. 906.68 determined based on Median of the 3 historical models.
Fair Value [Median EV / EBIDTA Model] : Rs. 881.35
Fair Value [Median EV / Sales Model] : Rs. 909.97
Fair Value [Median Price / Sales Model] : Rs. 906.68
Median Fair Value of CIPLA : Rs. 906.68

Is CIPLA trading at a Premium or Discount?

As on 24-Sep-2021, CIPLA is trading at a Premium of 7% based on the estimates of Median Intrinsic Value!

What is the Financial Performance of Industry Peers of CIPLA ?

Check out Annual Financials of Industry Peers
Share Price & Financials of SUN PHARMACEUTICAL INDUSTRIES LTD | BOM: 524715 | NSE: SUNPHARMA
Share Price & Financials of DIVIS LABORATORIES LTD | BOM: 532488 | NSE: DIVISLAB
Share Price & Financials of DR REDDYS LABORATORIES LTD | BOM: 500124 | NSE: DRREDDY
Share Price & Financials of GLAND PHARMA LTD | BOM: 543245 | NSE: GLAND
Check out Quarterly Results of Industry Peers
Quarterly Results of SUN PHARMACEUTICAL INDUSTRIES LTD
Quarterly Results of DIVIS LABORATORIES LTD
Quarterly Results of DR REDDYS LABORATORIES LTD
Quarterly Results of GLAND PHARMA LTD

What are the Frequent Comparisons in this Industry?

Compare Analytics
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs DR REDDYS LABORATORIES LTD
CIPLA LTD vs GLAND PHARMA LTD vs PIRAMAL ENTERPRISES LTD
CADILA HEALTHCARE LTD vs TORRENT PHARMACEUTICALS LTD vs ALKEM LABORATORIES LTD
LUPIN LTD vs AUROBINDO PHARMA LTD vs BIOCON LTD
ABBOTT INDIA LTD vs LAURUS LABS LTD vs IPCA LABORATORIES LTD
Browse Market Cap of Industry Peers
Market Cap of SUN PHARMACEUTICAL INDUSTRIES LTD
Market Cap of DIVIS LABORATORIES LTD
Market Cap of DR REDDYS LABORATORIES LTD
Market Cap of GLAND PHARMA LTD

Disclosure

SEBI Research Analyst
The Founder of this website, Mr. Rohit Katiyar is registered with SEBI as a Research Analyst [INH000007377].


All Stocks : A - Z

ALL   A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z